Adicet Bio, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Adicet Bio, Inc. (ACET) reported Cash and Cash Equivalents, Period Increase (Decrease) of $16.58 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-11-05
- Adicet Bio, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $2.25M.
- Adicet Bio, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $14.19M.
- Adicet Bio, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $139.00K, a 99.83% decline year-over-year.
- Adicet Bio, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$15.81M, a 132.02% decline year-over-year.
- Adicet Bio, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$46.31M, a 186.80% decline from fiscal 2017.
- Adicet Bio, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $53.35M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $16.44M derived: sum of 2 quarters · filed 2019-11-05 | $16.58M 10-Q · filed 2019-11-05 | $765.00K derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-06-30 | $14.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $14.33M 10-Q · filed 2019-08-14 | -$1.49M derived: sum of 3 quarters · filed 2019-08-14 | -$29.98M derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-03-31 | $139.00K 10-Q · filed 2019-05-15 | -$15.68M derived: sum of 2 quarters · filed 2019-05-15 | -$44.17M derived: sum of 3 quarters · filed 2019-11-05 | -$128.52M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-12-31 | -$15.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$44.31M derived: sum of 2 quarters · filed 2019-11-05 | -$128.66M derived: sum of 3 quarters · filed 2019-11-05 | -$46.31M 10-K · filed 2019-03-18 |
| 2018-09-30 | -$28.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$112.85M derived: sum of 2 quarters · filed 2019-11-05 | -$30.49M 10-Q · filed 2019-11-05 | $18.89M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | -$84.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$2.00M 10-Q · filed 2019-08-14 | $47.39M derived: sum of 3 quarters · filed 2019-08-14 | $48.04M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $82.36M 10-Q · filed 2019-05-15 | $131.74M derived: sum of 2 quarters · filed 2019-05-15 | $132.40M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | $49.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $50.04M derived: sum of 2 quarters · filed 2019-03-18 | $53.35M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $655.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $3.96M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $3.31M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |